|
Mar 11
|
Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates
|
|
Mar 11
|
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results
|
|
Feb 24
|
Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
|
|
Oct 4
|
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
|
|
Apr 16
|
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
|
|
Dec 7
|
Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data
|
|
Sep 5
|
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
|
|
Sep 5
|
Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
|